ALKS - Alkermes plc Sales Growth YoY (TTM)

Brandmark of Alkermes plc (ALKS)

Alkermes plc net profit is based on the development of innovative psychiatric therapies and the implementation of extended-release drug delivery systems. Year-over-year sales dynamics over the last four quarters visualize this process, where the 15.40 indicator expresses the state of the metric. Stability is guaranteed by the neutral geopolitical status of the Irish business, while primary revenues are generated by complex injections for patients with schizophrenia and addictions.

ALKS (Alkermes) Sales Growth YoY (Last Twelve Months) history from 02/11/2024 to 11/17/2026

Summary analytical data breakdowns for Alkermes (ALKS)

- market value and analyst target forecast:
Analysis of all company metrics:ALKS - Alkermes Inc.
Manufactured product of alkermes.com

Alkermes plc specializes in developing treatments for mental health disorders and addictions. This metric captures the trend of total revenue over the last twelve months relative to the previous year. By analyzing the trailing twelve-month (TTM) sales growth, an investor tracks the effectiveness of the company's patent strategy and licensing streams. Steady growth here confirms the expansion of Alkermes plc in the global neuropharmaceutical market, signaling the fundamental resilience of the business.